Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Chemotherapy-Induced Nausea and Vomiting
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology…
- Trial name
- EVOLVE_CINV (NCT03649230)
- Testing
- 300mg netupitant/0.5mg palonosetron hydrochloride
- Where
- 17 sites in Canada
- Volunteers
- 207 people
- Sponsor
- Purdue Pharma, Canada
Nausea and Vomiting, Postoperative, Nausea With Vomiting Chemotherapy-Induced
Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
This was an open-label, balanced, two-treatment, two-period, randomized sequence crossover bioequivalence study with a 7-day washout between periods. Each treatment was administered after an overnight (10 hours) fast.
- Trial name
- 01905/08-09 (NCT01217190)
- Testing
- Ondansetron (ODFS), Zofran (ODT)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MonoSol Rx
Cancer, Chemotherapy-Induced Nausea and Vomiting
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a phase III study designed to demonstrate the superiority of single-dose 90 mg intravenous (IV) casopitant over placebo, each in combination with ondansetron and dexamethasone, for the prevention of emesis over the first…
- Conditions
- Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
- Trial name
- NCT00891761
- Testing
- Dexamethasone, IV casopitant (active), Ondansetron
- Where
- 3 sites in United States, Canada
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)
Multicenter, randomized, open-label, paralled-group, active-controlled study. The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) compared with the intravenous and oral Granisetron in…
- Trial name
- NCT01662687
- Testing
- Sancuso patch, Kytril inj.+Kytril tab.
- Where
- South Korea
- Volunteers
- 276 people
- Sponsor
- LG Life Sciences
Vomiting, Nausea
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
The purpose of this study is to compare the efficacy and safety of ramosetron plus dexamethasone injection with granisetron plus dexamethasone injection for the prevention of chemotherapy-induced vomiting and nausea.
- Trial name
- NCT00272285
- Testing
- Ramosetron, Granisetron
- Where
- 2 sites in Taiwan
- Volunteers
- 287 people
- Sponsor
- Astellas Pharma Inc
Nausea and Vomiting, Chemotherapy-Induced
A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers
GW679769 may affect liver enzymes that metabolize warfarin. This study is designed to test the extent of the GW679769 affect on Warfarin levels in humans.
- Trial name
- NCT00404274
- Testing
- Casopitant (GW679769) oral tablets, Warfarin oral tablets
- Where
- 2 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea, Vomiting
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to determine whether palonosetron is tolerate and effective in preventing chemotherapy-induced nausea and vomiting in oriental population.
- Conditions
- Nausea, Vomiting, Chemotherapy
- Trial name
- NCT00503386
- Testing
- Palonosetron, Granisetron
- Where
- 6 sites in China
- Volunteers
- 144 people
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Nausea, Vomiting
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
This protocol will study an investigational drug treatment plan against standard therapy in the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast cancer who are to be treated with up to 4…
- Conditions
- Nausea, Vomiting, Breast Neoplasms
- Trial name
- NCT00092183
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 3 days
- Volunteers
- 866 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea, Vomiting
A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)
This is a Phase 2, randomized, multicenter, parallel-group, double-blind, placebo-controlled study of various doses of SCH 619734 in subjects receiving cisplatin-based chemotherapy.
- Trial name
- NCT00394966
- Testing
- SCH 619734 Dose 1, SCH 619734 Dose 2, SCH 619734 Dose 3
- Volunteers
- 450 people
- Sponsor
- Schering-Plough
Neoplasms, Nausea
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of single IV doses of Onicit® (Palonosetron) 0.25 mg in the prevention of acute and delayed nausea and vomiting associated with moderate and highly emetogenic…
- Conditions
- Neoplasms, Nausea, Vomiting
- Trial name
- NCT00684463
- Testing
- Palonosetron
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting (CINV)
Safety Study of Repeat Doses of SUSTOL in Adults
This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL®…
- Trial name
- NCT05434663
- Testing
- SUSTOL
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Heron Therapeutics
Nausea and Vomiting, Chemotherapy-Induced
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of…
- Trial name
- NCT00601172
- Testing
- Casopitant, Dexamethasone, Ondansetron
- Where
- 96 sites in United States, Belgium and 9 more
- Volunteers
- 710 people
- Sponsor
- GlaxoSmithKline
Chemotherapy-Induced Nausea and Vomiting
To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
Compared With Fosaprepitant dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of QLM2010 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly…
- Trial name
- NCT07081256
- Testing
- QLM2010 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
- Where
- China
- Volunteers
- 665 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chemotherapy-Induced Nausea and Vomiting
Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)
This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a non-U.S. marketed formulation of ondansetron.
- Trial name
- NCT00972595
- Testing
- ondansetron clinical trial formulation, ondansetron marketed formulation
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
GW679769 may affect liver enzymes that metabolize dexamethasone and ondansetron. This study is designed to test the safety and the extent of the GW679769 affect on dexamethasone and ondansetron levels in humans.
- Trial name
- NCT00437229
- Testing
- Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting
A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults.
- Trial name
- NCT00990821
- Testing
- 90 mg MK-0517 (PS80), 100 mg MK-0517 (PS80), 100 MK-0517 (PS80) + 2 mg midazolam
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)
This is a multicenter, randomized, open-label, paralleled-group, active-controlled study. The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) efficacy compared with the ondansetron…
- Trial name
- NCT01659775
- Testing
- Sancuso patch, Zofran inj.+Zofran tab.
- Where
- South Korea
- Volunteers
- 389 people
- Sponsor
- LG Life Sciences
Chemotherapy-Induced Nausea and Vomiting
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV)…
- Trial name
- NCT00787566
- Testing
- Intranasal granisetron
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
- Trial name
- NCT00460707
- Testing
- Casopitant 150 mg, Ketoconazole, Casopitant 50 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline